SCHEMBL1648630

SCHEMBL1648630

Nc1nc(N)c2nc(-c3cccc(O)c3)c(-c3ccccc3O)nc2n1

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PIK3CG P48736 12/20 0.81
▸ PIK3CA P42336 2/20 0.81
▸ PIK3CB P42338 2/20 0.81
▸ MTOR P42345 2/20 0.81
▸ PIK3CD O00329 1/20 0.81
▸ PIK3C2B O00750 1/20 0.81
▸ PDXK O00764 1/20 0.81
▸ GAK O14976 1/20 0.81
▸ MAP3K7 O43318 1/20 0.81
▸ RIPK2 O43353 1/20 0.81
▸ PIP5K1C O60331 1/20 0.81
▸ STK16 O75716 1/20 0.81
▸ PIK3C2G O75747 1/20 0.81
▸ PRKD3 O94806 1/20 0.81
▸ OXSR1 O95747 1/20 0.81
▸ LATS1 O95835 1/20 0.81
▸ ABL1 P00519 1/20 0.81
▸ EGFR P00533 1/20 0.81
▸ ERBB2 P04626 1/20 0.81
▸ LCK P06239 1/20 0.81

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tg100-115 SCHEMBL29369340 0.90 PIK3CG (1.00) PIK3CGPIK3CAPIK3CBMTORPIK3CD
Tg100-115 SCHEMBL360279 0.90 PIK3CG (1.00) PIK3CGPIK3CAPIK3CBMTORPIK3CD
Tg100-115 SCHEMBL29411790 0.90 PIK3CG (1.00) PIK3CGPIK3CAPIK3CBMTORPIK3CD
Tg100-115 SCHEMBL29506727 0.90 PIK3CG (1.00) PIK3CGPIK3CAPIK3CBMTORPIK3CD
Tg100-115 SCHEMBL29361550 0.90 PIK3CG (1.00) PIK3CGPIK3CAPIK3CBMTORPIK3CD
Tg100-115 SCHEMBL31238338 0.90 PIK3CG (1.00) PIK3CGPIK3CAPIK3CBMTORPIK3CD
Tg100-115 SCHEMBL3539255 0.88 PIK3CG (0.97) PIK3CGPIK3CAPIK3CBMTORPIK3CD
Tg100-115 SCHEMBL3539251 0.88 PIK3CG (0.97) PIK3CGPIK3CAPIK3CBMTORPIK3CD
Tg100-115 SCHEMBL3537211 0.88 PIK3CG (0.97) PIK3CGPIK3CAPIK3CBMTORPIK3CD
SCHEMBL13403357 0.82 PIK3CG (0.85) PIK3CGPIK3CAPIK3CBMTORPIK3CD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3377068-A1 COMBINATION THERAPY OF TETRACYCLIC QUINOLONE ANALOGS FOR TREATING CANCER Senhwa Biosciences, Inc. (TW) 2018-09-26 — — EP disclosed
EP-2483686-A1 BIOMARKERS FOR PREDICTING THE SENSITIVITY AND RESPONSE OF PROTEIN KINASE CK2-MEDIATED DISEASES TO CK2 INHIBITORS Cylene Pharmaceuticals, Inc. (US) 2012-08-08 — — EP disclosed
WO-2011041785-A1 BIOMARKERS FOR PREDICTING THE SENSITIVITY AND RESPONSE OF PROTEIN KINASE CK2-MEDIATED DISEASES TO CK2 INHIBITORS CYLENE PHARMACEUTICALS, INC. (US) 2011-04-07 — — WO disclosed
Send feedback